@TalhaBadarMD@Daver_Leukemia Sir very informative. It definitely provides a new ray of hope to AML patients. Is the CD123 CAR T trial still recruiting new patients? How can I enrol R/R cases from our center FMRI.
It is a “dogma” indeed! I am guilty of buying into it in the past. Now with amazing Bispecific data, trispecifics in the horizon, and more trials testing fixed duration BsAb approach, we have to discuss the risk/benefit of both sequencing approaches with patients acknowledging that we don’t really know what the best sequence is. This is a question that cannot be reliably answered by retrospective data, such as the one that we saw in #ASCO26.
After ASCO, its' #EHA2026 season- AND THIS YEAR, I AM READING #MULTIPLEMYELOMA DIFFERENTLY.
Not as a list of exciting abstracts.
But as a blueprint for what focused myeloma care must actually deliver.
➡️ A few EHA 2026 themes I am watching closely:
▪️ 1. Frontline myeloma: depth is important, but patient selection is everything.
CEPHEUS, IDEAL and DREAMM-9 continue the global movement towards deeper frontline responses.
For us, the best frontline strategy is not just the most powerful regimen.
It is the most appropriate, deliverable and sustainable one.
▪️ 2. Frailty and renal dysfunction cannot be side notes.
AGMT MM04 wth isatuximab-Rd in elderly NDMM, and iberdomide–daratumumab- dexamethasone analysed by renal function, are very relevant to our real-world patients.
Many patients do not come to us as “trial-perfect” patients.
They come with anemia, renal dysfunction, infections, bone disease, frailty, delayed diagnosis & financial limitations.
▪️ 3. Relapsed myeloma: sequencing is becoming the real science.
MonumenTAL-3, MajesTEC-9, MajesTEC-3, SUCCESSOR-2, DREAMM-7/9 and CAMMA-2 all point to the same direction.
The relapse clinic is becoming target-based.
For us, many patients may not get unlimited lines of therapy.
The sequence we choose today may decide what remains possible tomorrow.
▪️ 4. AL amyloidosis deserves its own pathway.
LINKER-AL2 with linvoseltamab in relapsed/refractory systemic AL amyloidosis is important beyond the molecule.
The bigger challenge for us is not just access to newer therapy.
It is earlier diagnosis and faster referral.
▪️ 5. Biology cannot remain optional.
The whole-genome sequencing/immunotherapy-resistance abstract is an important reminder: Relapse has biology.
We need to ask better biological questions before we choose the next treatment.
As EHA 2026 begins globally, we also launch the Centre of Excellence for Myeloma & Lymphoma at Fortis Gurugram on 11th June. This week feels special.
#mmsm #EHA2026
Myeloma care in India needs focus.
On 11th June, we take that step.
At FMRI Gurugram, we launch the Centre of Excellence for Myeloma & Lymphoma.
For me, this is deeply personal.
Some diseases you treat. Some diseases shape the way you think as a hematologist. For me, #MultipleMyeloma has been that disease.
Built around focus. Driven by science. Centred on patients.
#MultipleMyeloma #Hematology #mmsm
@rajshekharucms Totally agreed 💯. We use bispecifics in penta class refractory myeloma patients before CAR T cell therapy at our center in India with very good response rates and PFS rates
@b_2boysmom1310@rajshekharucms@FDAOncology Totally agreed 💯. We have personally given drug free interval to patients on teclistamab after achieving MRD negativity and they are doing fine and infections are minimal
🇺🇸 WARREN BUFFETT: "I can end the U.S. deficit problem in 5 minutes."
"Just pass a law that any time there's a deficit of more than 3% of GDP, all members of Congress are ineligible for re-election."
@narendramodi explore India s tourism potential . Restore and aesthetically clean all old monuments.provide all inclusive packages to international tourists. Promote tourism at priority levels.
@narendramodi need to use Artificial Intelligence in tenders, permissions, and other aspects of policy approvals in government for actually improving ease of doing business index in India
@nsitharaman need to use Artifical Intelligence in tenders, permissions, and other aspects of policy approvals in government for actually improving ease of doing business index in India.
@nsitharaman need to use Artifical Intelligence in tenders, permissions, and other aspects of policy approvals in government for actually improving ease of doing business index in India.